New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. November 15, 2021 – Philadelphia. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the...
Philadelphia, 18 October 2021 – WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading...
March 29, 2021 – Philadelphia, PA – We are pleased to announce that Ms. Michie Ong will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Senior Director of Global Quality and Compliance. In this role, Ms. Michie Ong will be responsible for setting the...
March 4, 2021 – Philadelphia, PA – We are pleased to announce that Ms. Haiyan Liu will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Executive Director of Analysis and Testing. Ms. Haiyan Liu will be leading WuXi ATU China Analytical Development and...
PHILADELPHIA and OXFORD, March 2, 2021 – WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a...
February 22, 2021 – Philadelphia, PA – We are pleased to announce that James Chen will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Senior Director of Quality. Mr. James Chen will be leading WuXi ATU China Quality organization and working closely with...
